vs
Beam Therapeutics Inc.（BEAM）与Empire State Realty Trust, Inc.（ESRT）财务数据对比。点击上方公司名可切换其他公司
Empire State Realty Trust, Inc.的季度营收约是Beam Therapeutics Inc.的1.7倍（$190.3M vs $114.1M），Beam Therapeutics Inc.净利率更高（214.1% vs 1.6%，领先212.5%），Beam Therapeutics Inc.同比增速更快（279.5% vs 5.7%）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
帝国州房地产信托是一家美国房地产投资信托企业，持有并运营纽约大都会区的优质办公、零售及住宅物业，旗下资产包括地标性建筑帝国大厦，主打可持续运营模式，服务各类租户及住户，专注实现长期资产增值。
BEAM vs ESRT — 直观对比
营收规模更大
ESRT
是对方的1.7倍
$114.1M
营收增速更快
BEAM
高出273.8%
5.7%
净利率更高
BEAM
高出212.5%
1.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $190.3M |
| 净利润 | $244.3M | $3.0M |
| 毛利率 | — | — |
| 营业利润率 | -15.3% | 15.5% |
| 净利率 | 214.1% | 1.6% |
| 营收同比 | 279.5% | 5.7% |
| 净利润同比 | 370.4% | -73.7% |
| 每股收益（稀释后） | $2.53 | $0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMESRT
| Q1 26 | — | $190.3M | ||
| Q4 25 | $114.1M | $199.2M | ||
| Q3 25 | — | $197.7M | ||
| Q2 25 | — | $191.3M | ||
| Q1 25 | — | $180.1M | ||
| Q4 24 | — | $197.6M | ||
| Q3 24 | — | $199.6M | ||
| Q2 24 | — | $189.5M |
净利润BEAMESRT
| Q1 26 | — | $3.0M | ||
| Q4 25 | $244.3M | $32.2M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $11.4M | ||
| Q1 25 | — | $15.8M | ||
| Q4 24 | — | $18.8M | ||
| Q3 24 | — | $22.8M | ||
| Q2 24 | — | $28.6M |
营业利润率BEAMESRT
| Q1 26 | — | 15.5% | ||
| Q4 25 | -15.3% | 17.8% | ||
| Q3 25 | — | 19.9% | ||
| Q2 25 | — | 18.4% | ||
| Q1 25 | — | 14.3% | ||
| Q4 24 | — | 21.7% | ||
| Q3 24 | — | 22.7% | ||
| Q2 24 | — | 20.8% |
净利率BEAMESRT
| Q1 26 | — | 1.6% | ||
| Q4 25 | 214.1% | 16.1% | ||
| Q3 25 | — | 6.9% | ||
| Q2 25 | — | 6.0% | ||
| Q1 25 | — | 8.8% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | 15.1% |
每股收益（稀释后）BEAMESRT
| Q1 26 | — | $0.20 | ||
| Q4 25 | $2.53 | $0.11 | ||
| Q3 25 | — | $0.05 | ||
| Q2 25 | — | $0.04 | ||
| Q1 25 | — | $0.05 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | — | $0.08 | ||
| Q2 24 | — | $0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $68.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $1.8B |
| 总资产 | $1.5B | $4.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BEAMESRT
| Q1 26 | — | $68.8M | ||
| Q4 25 | $1.2B | $132.7M | ||
| Q3 25 | — | $154.1M | ||
| Q2 25 | — | $94.6M | ||
| Q1 25 | — | $187.8M | ||
| Q4 24 | — | $385.5M | ||
| Q3 24 | — | $421.9M | ||
| Q2 24 | — | $535.5M |
股东权益BEAMESRT
| Q1 26 | — | $1.8B | ||
| Q4 25 | $1.2B | $1.1B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $1.0B |
总资产BEAMESRT
| Q1 26 | — | $4.4B | ||
| Q4 25 | $1.5B | $4.5B | ||
| Q3 25 | — | $4.1B | ||
| Q2 25 | — | $4.1B | ||
| Q1 25 | — | $4.1B | ||
| Q4 24 | — | $4.5B | ||
| Q3 24 | — | $4.4B | ||
| Q2 24 | — | $4.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | — |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | — |
| 自由现金流率自由现金流/营收 | -76.3% | — |
| 资本支出强度资本支出/营收 | 3.3% | 10.0% |
| 现金转化率经营现金流/净利润 | -0.34× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BEAMESRT
| Q1 26 | — | — | ||
| Q4 25 | $-83.3M | $249.1M | ||
| Q3 25 | — | $105.3M | ||
| Q2 25 | — | $26.7M | ||
| Q1 25 | — | $83.1M | ||
| Q4 24 | — | $260.9M | ||
| Q3 24 | — | $102.8M | ||
| Q2 24 | — | $37.1M |
自由现金流BEAMESRT
| Q1 26 | — | — | ||
| Q4 25 | $-87.0M | $50.6M | ||
| Q3 25 | — | $72.8M | ||
| Q2 25 | — | $-55.1M | ||
| Q1 25 | — | $41.1M | ||
| Q4 24 | — | $88.0M | ||
| Q3 24 | — | $-65.1M | ||
| Q2 24 | — | $19.5M |
自由现金流率BEAMESRT
| Q1 26 | — | — | ||
| Q4 25 | -76.3% | 25.4% | ||
| Q3 25 | — | 36.8% | ||
| Q2 25 | — | -28.8% | ||
| Q1 25 | — | 22.8% | ||
| Q4 24 | — | 44.5% | ||
| Q3 24 | — | -32.6% | ||
| Q2 24 | — | 10.3% |
资本支出强度BEAMESRT
| Q1 26 | — | 10.0% | ||
| Q4 25 | 3.3% | 99.6% | ||
| Q3 25 | — | 16.5% | ||
| Q2 25 | — | 42.8% | ||
| Q1 25 | — | 23.4% | ||
| Q4 24 | — | 87.5% | ||
| Q3 24 | — | 84.1% | ||
| Q2 24 | — | 9.3% |
现金转化率BEAMESRT
| Q1 26 | — | — | ||
| Q4 25 | -0.34× | 7.74× | ||
| Q3 25 | — | 7.72× | ||
| Q2 25 | — | 2.35× | ||
| Q1 25 | — | 5.27× | ||
| Q4 24 | — | 13.88× | ||
| Q3 24 | — | 4.51× | ||
| Q2 24 | — | 1.30× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
ESRT
| Rental revenue (1) | $166.1M | 87% |
| Observatory revenue | $18.5M | 10% |
| Other revenue and fees | $4.1M | 2% |
| Lease termination fees | $1.4M | 1% |
| Third-party management and other fees | $277.0K | 0% |
